Apixaban for Treatment of Embolic Stroke of Undetermined Source (ATTICUS)
Apixaban for Treatment of Embolic Stroke of Undetermined Source (ATTICUS Randomized Trial)
Sponsor: Bristol-Myers Squibb
This PHASE3 trial investigates Embolic Stroke of Undetermined Source and is currently completed. Bristol-Myers Squibb leads this study, which shows 11 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2021 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE3
▶ Show 6 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Aug 2019 — Dec 2020 [monthly]
Recruiting PHASE3
-
Jan 2019 — Aug 2019 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jan 2019 [monthly]
Recruiting PHASE3
-
Apr 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Apr 2017 [monthly]
Recruiting PHASE3
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Medtronic
- University Hospital Tuebingen
- ZKS and IKEaB Tübingen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Berlin, Germany , Bonn, Germany , Coburg, Germany , Friedrichshafen, Germany , Göttingen, Germany , Halle, Germany , Kiel, Germany , Ludwigsburg, Germany , Magdeburg, Germany , Merseburg, Germany and 5 more locations